HAE — Stock Film
STOCK FILMSCENE 1/12HAE · $101
Stock Expert AI presents
HAE
Haemonetics Corporation
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Haemonetics Corporation. What it actually does.

Provides automated plasma collection devices and related disposables. Offers integrated information technology platforms for plasma customers. Now — the numbers.

on the stock market since 1991
3,009 employees
$4.6B market value
WHERE DOES THE MONEY COME FROM?
27%Hospital
HospitalPlasma 24%Hemostasis Management, Hospital 17%Interventional Technologies, Hospital 11%Blood Center 10%Other 10%
27% of all revenue comes from a single line: Hospital.

Revenue is spread across several lines; no single product carries the company.

Revenue last year:
$1.3B
The net profit left over:
$97.3M
Out of every $100 in sales, $7 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 7%

This is an established company with proven profits.

Cash on hand:
$245.4M
Total debt:
$1.2B
The debt outweighs the cash.

The gap is $979.1M. In times of high interest rates, a gap like that can squeeze a company.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
8 / 8
EXPECTATIONS MET OR BEATEN
8
Nov 2024
Aug 2026
8 TIMES IN THE LAST 8 QUARTERS
It clears the bar, quarter after quarter.
What executives did with their own stock over the last 12 months:
33 buy20 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
87
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
41
weak

Clearly below the class average.

VALUATION
56
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

PRICE MOMENTUM
84
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/2
Delivers on expectations

It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 33 buys and 20 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
A rich price tag

The company’s market value is 47 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/2
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 41/100.

FINALE · THE GRADE
A
76 / 100 · MoonshotScore

On our five-subject report card, HAE sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: HAE is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 10, 2026 · stockexpertai.com · Stock Film